Does Cosentyx Worsen Pre-Existing Heart Conditions?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, shows no overall increased risk of major cardiovascular events (MACE) like heart attacks or strokes in patients with pre-existing conditions. Pooled trial data from over 10,000 patients found similar MACE rates (0.2-0.6%) compared to placebo, even in those with baseline cardiovascular disease.[1][2]
Cardiovascular Safety in High-Risk Patients
In trials like FUTURE and MEASURE, patients with prior heart disease tolerated Cosentyx similarly to placebo groups. A 5-year extension study reported stable rates of hypertension (3-5%) and no excess heart failure signals. Real-world registries, such as the US CorEvitas Psoriasis Registry, confirm low incidence of new cardiac events post-treatment.[3][4]
What Happens with Specific Conditions Like Heart Failure?
Cosentyx carries no specific warnings for congestive heart failure, unlike some biologics (e.g., JAK inhibitors). Post-marketing data through 2023 shows rare reports (<0.1%) of worsening heart failure, often confounded by comorbidities. Novartis monitoring found no causal link, but clinicians monitor ejection fraction in severe cases.[5][6]
How Does It Compare to Other Biologics for Heart Patients?
| Biologic | MACE Risk vs Placebo | Heart Failure Notes |
|----------|----------------------|---------------------|
| Cosentyx | Neutral | No increase |
| Humira (adalimumab) | Neutral/slight increase in some trials | Rare worsening |
| Stelara (ustekinumab) | Neutral | Lowest CV signals |
| Xeljanz (tofacitinib) | Elevated (black box warning) | Avoid in HF |
Cosentyx edges out TNF inhibitors for patients with moderate CV risk due to fewer inflammatory pathway effects on plaques.[7][8]
Monitoring and Who Should Avoid It?
Patients with uncontrolled hypertension or recent MI wait 3-6 months before starting. Routine checks include blood pressure and lipids at baseline and every 3 months. Avoid if active endocarditis or severe uncontrolled heart disease. Pregnancy registries show no fetal CV risks.[9]
Ongoing Studies and Long-Term Data
Phase 4 trials (e.g., NCT04835731) track CV outcomes in high-risk psoriasis patients through 2026. FDA label updated 2024 reflects neutral profile based on 12+ years of data.10
[1]: Novartis Cosentyx Prescribing Information (FDA, 2024) - link
[2]: Bissonnette et al., J Am Acad Dermatol (2018) - link
[3]: Deodhar et al., Lancet (2020) - link
[4]: Lebwohl et al., J Am Acad Dermatol (2023) - link
[5]: FAERS Database (FDA, Q1 2024) - link
[6]: Novartis Safety Update (2023) - link
[7]: Ritchlin et al., Arthritis Rheumatol (2022) - link
[8]: Ytterberg et al., NEJM (2021) - link
[9]: Cosentyx Pregnancy Registry (MotherToBaby, 2024) - link